ANVS
Annovis Bio Inc

9,437
Loading...
Loading...
News
all
press releases
All You Need to Know About Annovis Bio (ANVS) Rating Upgrade to Buy
Zacks·4mo ago
News Placeholder
More News
News Placeholder
Annovis Bio Stock Among Retail's Top Draws After FDA Nod For Final Phase 3 Alzheimer’s Study Protocol
According to CEO Maria Maccecchini, the new streamlined design potentially enables a New Drug Application filing based on the six-month data.
Stocktwits·9mo ago
News Placeholder
Annovis Bio Stock Surges As Analyst Reiterates ‘Buy’ On Alzheimer’s Drug Progress: Retail Stays Bullish
The FDA recently granted clearance for the company to proceed to Phase 3 trials, following successful Phase 2 results that showed improvement in Alzheimer’s patients.
Stocktwits·1y ago
News Placeholder
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More PR Newswire NEW YORK...
PR Newswire·1y ago
News Placeholder
Big Pharma’s $13.7B Alzheimer’s Drug Market Has a Progress Problem: Here Are Three Small-Cap Biotech Stocks That Could Disrupt the Market
Small biotech firms like Cassava Sciences, INmune Bio, and Annovis Bio are developing innovative Alzheimer’s treatments, disrupting big pharma’s dominance in the $13.7B market. For those targeting groundbreaking therapies, high-risk, high-reward investments lie ahead.
Stocktwits Contributor·1y ago
News Placeholder
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition PR Newswire NEW YORK, Oct. 1, 2024...
PR Newswire·1y ago
News Placeholder
Annovis Bio Raises $7 Million from Warrant Exercises
An update from Annovis Bio (ANVS) is now available. Annovis Bio, Inc. has successfully exercised 0.8 million warrants issued in November 2023, resu...
TipRanks Financial Blog·1y ago
News Placeholder
Maxim Group Sticks to Its Hold Rating for Annovis Bio (ANVS)
Maxim Group analyst Jason McCarthy maintained a Hold rating on Annovis Bio (ANVS Research Report) yesterday. The company's shares opened today at...
TipRanks Financial Blog·1y ago
News Placeholder
Peering Into Annovis Bio's Recent Short Interest
read more...
Benzinga·1y ago
News Placeholder
What's Going On With Annovis Shares Today?
Annovis Bio shares rise in premarket trading on positive Phase III Parkinson's study results for buntanetap, showing cognitive improvements and stability compared to placebo. read more...
Benzinga·1y ago

Latest ANVS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.